Fig. 1: Investigator-assessed progression-free survival (A) overall, (B) by del(17)(p13.1) and/or mutated TP53 status, and (C) by IGHV mutation status. | Leukemia

Fig. 1: Investigator-assessed progression-free survival (A) overall, (B) by del(17)(p13.1) and/or mutated TP53 status, and (C) by IGHV mutation status.

From: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

Fig. 1

aHazard ratio was based on stratified Cox-Proportional-Hazards model; bP value was based on stratified log-rank test; cHazard ratio was based on unstratified Cox-Proportional-Hazards model. dP value was based on unstratified log-rank test. A acalabrutinib, CI confidence interval, Clb chlorambucil, HR hazard ratio, IGHV immunoglobulin heavy chain variable region, mTP53 mutated TP53, NR not reached, O obinutuzumab, PFS progression-free survival, w/o without.

Back to article page